rosiglitazone has been researched along with ciglitazone in 60 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (11.67) | 18.2507 |
| 2000's | 38 (63.33) | 29.6817 |
| 2010's | 13 (21.67) | 24.3611 |
| 2020's | 2 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cantello, BC; Cawthorne, MA; Cottam, GP; Duff, PT; Haigh, D; Hindley, RM; Lister, CA; Smith, SA; Thurlby, PL | 1 |
| Beck, KD; Cobb, JE; Correa, ID; Cowan, DJ; Kliewer, SA; Lehmann, JM; Moore, LB; Prakash, SR; Wiethe, RW; Willson, TM | 1 |
| Blanchard, SG; Brackeen, MF; Brown, KK; Cobb, JE; Collins, JL; Harrington, WW; Hashim, MA; Henke, BR; Hull-Ryde, EA; Kaldor, I; Kliewer, SA; Lake, DH; Leesnitzer, LM; Lehmann, JM; Lenhard, JM; Miller, JF; Mook, RA; Noble, SA; Oliver, W; Orband-Miller, LA; Parks, DJ; Plunket, KD; Szewczyk, JR; Willson, TM | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Carroll, RT; Darvesh, AS; Funk, MO; Geldenhuys, WJ; Van der Schyf, CJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Darvesh, AS; Geldenhuys, WJ; Leeper, TC; Morris, DL; Sullivan, PG; Yonutas, HM | 1 |
| Adams, WJ; Artman, GD; Colca, JR; Gadwood, RC; Kletzien, RF; Larsen, SD; Lee, PH; McDonald, WG; Parker, TT; Tanis, SP; Zeller, JB | 1 |
| Chen, S; Chen, Y; Fu, L; Zhang, L | 1 |
| Aamir Javed, M; Ikram, M; Jadoon, R; Mahnashi, MH; Rashid, U; Sadiq, A; Saeed Jan, M; Shahid, M | 1 |
| Kliewer, SA; Lehmann, JM; Lenhard, JM; Morris, DC; Patel, I; Willson, TM | 1 |
| Akatsuka, H; Arakawa, K; Homma, K; Iijima, I; Inamasu, M; Kawanami, S; Matsumoto, M; Okumura, K; Ozeki, M; Saiga, Y; Watanabe, A; Yasuda, K | 1 |
| Dandine, M; Dauzats, M; Daviaud, D; Langin, D; Saulnier-Blache, JS; Viguerie-Bascands, N | 1 |
| Gerritsen, ME; Kowalski, J; Xin, X; Yang, S | 1 |
| Kuzuya, T | 1 |
| Brüne, B; Von Knethen A, A | 1 |
| Hupfeld, CJ; Weiss, RH | 1 |
| Berry, E; Gilmour, R; Helliwell, R; Keelan, J; Marvin, K; Mitchell, M; Nijmeijer, B; Sato, T | 1 |
| Frauwirth, KA; Lazar, MA; Rangwala, SM; Thompson, CB; Wang, YL | 1 |
| Chatterjee, PK; Cuzzocrea, S; Hattori, Y; McDonald, MC; Mota-Filipe, H; Pisano, B; Thiemermann, C; Wayman, NS | 1 |
| Battarbee, H; Coates, G; Nissim, I; Welbourne, T | 1 |
| Greenberg, AS; Mathys, JM; Rabbi, MF; Skolnik, PR | 1 |
| Burgermeister, E; Liscovitch, M; Tencer, L | 1 |
| Auwerx, J; Capron, M; Dombrowicz, D; Honda, K; Loyens, M; Papin, JP; Staels, B; Woerly, G | 1 |
| Gille, J; Kaufmann, R; Meissner, M; Reisinger, K; Staels, B; Stein, M; Suske, G; Urbich, C | 1 |
| Angeli, V; de Heer, HJ; Hammad, H; Hoogsteden, HC; Lambrecht, BN; Soullié, T; Trottein, F | 1 |
| Bai, AH; Chan, FK; Chan, KK; Chan, MW; Chan, VY; Fu, YG; Leung, WK; Sung, JJ; To, KF; Wu, JR; Yu, J | 1 |
| Bode, C; Ernst, S; Leugers, A; Lohrmann, J; Nordt, TK; Sobel, BE; Zirlik, A | 1 |
| Acerbi, G; Bartalena, L; Bogazzi, F; Brogioni, S; Cecchetti, D; Cosci, C; Gasperi, M; Guida, C; Martino, E; Raggi, F; Russo, D; Ultimieri, F; Vanacore, R; Viacava, P | 1 |
| Burgess, HA; Daugherty, LE; Lakatos, HF; Phipps, RP; Ray, DM; Redonnet, M; Sime, PJ; Thatcher, TH | 1 |
| Allred, CD; Kilgore, MW | 1 |
| D'Aprile, A; Henry, PJ; Hong, T; Mann, TS; Self, G | 1 |
| Hart, CM; Mazzella, LJ; Polikandriotis, JA; Rupnow, HL | 1 |
| Bonacci, JV; Fernandes, DJ; Quan, L; Stewart, AG; Taylor, CC; Ward, JE | 1 |
| Brunskill, NJ; Chana, RS | 1 |
| Jang, KY; Jang, YB; Kang, KP; Kim, DH; Kim, W; Lee, JE; Lee, S; Moon, SO; Park, SK; Sung, MJ | 1 |
| Aiello, A; Belfiore, A; Conte, E; Frasca, F; Genua, M; Murabito, A; Pandini, G; Sacco, A; Vigneri, R | 1 |
| Blann, E; Dial, S; Dragan, YP; Guo, L; Muskhelishvili, L; Schroth, G; Shi, L; Sun, Y; Zhang, L | 1 |
| Moseley, RH; Snow, KL | 1 |
| Brandt, U; Brüne, B; Dröse, S; Soller, M; von Knethen, A | 1 |
| Blay, J; Richard, CL | 1 |
| Ball, SG; Mughal, RS; O'Regan, DJ; Porter, KE; Turner, NA; Warburton, P | 1 |
| Giaginis, C; Theocharis, S; Tsantili-Kakoulidou, A | 1 |
| Fu, WM; Lin, CP; Lin, TH; Tang, CH; Yang, RS | 1 |
| Jang, SK; Kim, JH; Kim, WJ | 1 |
| Bianchi, A; Jouzeau, JY; Koufany, M; Moulin, D; Netter, P; Sebillaud, S | 1 |
| Akinyeke, TO; Lyles, BE; Moss, PE; Stewart, LV | 1 |
| Aleshin, S; Grabeklis, S; Hanck, T; Reiser, G; Sergeeva, M | 1 |
| Fantus, IG; Goldberg, HJ; Munk, S; Wang, H; Whiteside, C; Xia, L | 1 |
| Chopra, B; Georgopoulos, NT; Hinley, J; Nicholl, A; Oleksiewicz, MB; Southgate, J | 1 |
| Cheong, J; Ha, E; Kim, K; Kim, KH; Park, JY; Sakamoto, N | 1 |
| Lyles, BE; Moss, PE; Stewart, LV | 1 |
| Al-Alem, L; Curry, TE; Kilgore, MW; Southard, RC | 1 |
| Andersen, OS; Greathouse, DV; Hemmings, HC; Herold, KF; Rusinova, R; Sanford, RL | 1 |
| Arif, IS; Boateng, SY; Greco, F; Hooper, CL; Williams, AC | 1 |
| Furumura, M; Hashimoto, T; Karashima, T; Numata, S; Ohyama, B; Tanida, N; Teye, K; Yan, Y | 1 |
| Darrah, L; Ondrey, FG; Wudel, J; Wuertz, BR | 1 |
3 review(s) available for rosiglitazone and ciglitazone
| Article | Year |
|---|---|
Inhibiting Sodium Taurocholate Cotransporting Polypeptide in HBV-Related Diseases: From Biological Function to Therapeutic Potential.
Topics: Carcinoma, Hepatocellular; Hep G2 Cells; Hepatitis B; Hepatitis B virus; Hepatocytes; Humans; Interferons; Liver Neoplasms; Nucleotides; Organic Anion Transporters, Sodium-Dependent; Symporters; Virus Internalization | 2022 |
[The development of thiazolidinedione drugs as anti-diabetic agents].
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Mice; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists].
Topics: Animals; Arthritis, Rheumatoid; Chromans; Dimerization; Extracellular Matrix; Humans; Hypoglycemic Agents; Joint Diseases; Osteoarthritis; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR-beta; Rosiglitazone; Thiazolidinediones; Troglitazone | 2008 |
57 other study(ies) available for rosiglitazone and ciglitazone
| Article | Year |
|---|---|
[[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hemoglobins; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Structure-Activity Relationship; Thiazoles | 1994 |
The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones.
Topics: Animals; Cell Line; Hypoglycemic Agents; Mice; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship; Thiazoles; Transcription Factors | 1996 |
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
Topics: Administration, Oral; Aminopyridines; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; DNA-Binding Proteins; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Ligands; Lipids; Male; Mice; Oxazoles; Propionates; Radioligand Assay; Rats; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Stereoisomerism; Structure-Activity Relationship; Transcription Factors; Transfection; Tyrosine | 1998 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening.
Topics: Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Identification of small molecules that bind to the mitochondrial protein mitoNEET.
Topics: Hypoglycemic Agents; Ligands; Mitochondrial Proteins; Protein Binding; Small Molecule Libraries; Thiazolidinediones | 2016 |
PPARγ-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development.
Topics: Dose-Response Relationship, Drug; Drug Design; Humans; Insulin Resistance; Molecular Structure; PPAR gamma; Structure-Activity Relationship; Thiazolidinediones | 2018 |
Design, synthesis, in-vitro, in-vivo and ex-vivo pharmacology of thiazolidine-2,4-dione derivatives as selective and reversible monoamine oxidase-B inhibitors.
Topics: Hydrazones; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship; Thiazolidines | 2022 |
A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation.
Topics: Adipocytes; Animals; Binding, Competitive; Cell Differentiation; Cells, Cultured; Fibroblasts; Hypoglycemic Agents; Ligands; Mice; Microbodies; Prostaglandin D2; Prostaglandins; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation | 1995 |
Novel benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents. Synthesis and structure-activity relationships.
Topics: Animals; Benzopyrans; Benzoxazoles; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Male; Mice; Obesity; Pioglitazone; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Increase in uncoupling protein-2 mRNA expression by BRL49653 and bromopalmitate in human adipocytes.
Topics: Adipocytes; Adipose Tissue; Adult; Cells, Cultured; Culture Techniques; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Humans; Ion Channels; Leptin; Membrane Transport Proteins; Middle Aged; Mitochondrial Proteins; Palmitates; Proteins; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Transcriptional Activation; Tumor Necrosis Factor-alpha; Uncoupling Protein 2 | 1999 |
Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo.
Topics: Animals; Cell Differentiation; Cell Division; Cells, Cultured; Cornea; Eicosanoids; Endothelium, Vascular; Gene Expression Regulation; Humans; Ligands; Neovascularization, Physiologic; Prostaglandin D2; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 1999 |
Delayed activation of PPARgamma by LPS and IFN-gamma attenuates the oxidative burst in macrophages.
Topics: Animals; Cell Line; Cell Survival; Cells, Cultured; Escherichia coli; Genes, Reporter; Humans; Hypoglycemic Agents; Interferon-gamma; Lipopolysaccharides; Luciferases; Macrophages; Mice; Microbodies; Monocytes; NG-Nitroarginine Methyl Ester; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Respiratory Burst; Rosiglitazone; Tetradecanoylphorbol Acetate; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection | 2001 |
TZDs inhibit vascular smooth muscle cell growth independently of the cyclin kinase inhibitors p21 and p27.
Topics: Animals; Becaplermin; CDC2-CDC28 Kinases; Cell Cycle Proteins; Cell Division; Cells, Cultured; Culture Media, Serum-Free; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; DNA; Enzyme Inhibitors; Muscle, Smooth, Vascular; Oligonucleotides, Antisense; Platelet-Derived Growth Factor; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-sis; Rats; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Suppressor Proteins | 2001 |
15-deoxy-delta12,14-prostaglandin J2-induced apoptosis in amnion-like WISH cells.
Topics: Amino Acid Chloromethyl Ketones; Amnion; Apoptosis; Caspase Inhibitors; Caspases; Cell Survival; Cells, Cultured; Cysteine Proteinase Inhibitors; Enzyme Activation; Humans; Hypoglycemic Agents; Immunologic Factors; Ligands; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors | 2001 |
Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival.
Topics: Animals; Cell Death; Cell Survival; Cells, Cultured; Humans; Hypoglycemic Agents; Interleukin-3; Lymphocyte Activation; Membrane Potentials; Mice; Mice, Inbred C57BL; Mitochondria; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Rosiglitazone; T-Lymphocytes; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection; Up-Regulation | 2002 |
Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size.
Topics: Adult; Animals; Cardiotonic Agents; Cell Adhesion Molecules; Cell Line; Cells, Cultured; Chemokine CCL2; Clofibrate; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Humans; Ligands; Male; Membrane Proteins; Myocardial Infarction; Myocardial Reperfusion Injury; Pioglitazone; Prostaglandin D2; Prostaglandins A; Protein Isoforms; Pyrimidines; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Glitazones regulate glutamine metabolism by inducing a cellular acidosis in MDCK cells.
Topics: Acidosis; Alanine Transaminase; Animals; Cell Line; Chromans; Epithelial Cells; Glutamine; Hydrogen-Ion Concentration; Hypoglycemic Agents; Kidney; L-Lactate Dehydrogenase; Nitrogen; Nitrogen Isotopes; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Stimulation of peroxisome proliferator-activated receptors alpha and gamma blocks HIV-1 replication and TNFalpha production in acutely infected primary blood cells, chronically infected U1 cells, and alveolar macrophages from HIV-infected subjects.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cell Line; Chromans; Fenofibrate; HIV-1; Humans; Leukocytes, Mononuclear; Macrophages, Alveolar; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Necrosis Factor-alpha; Virus Replication | 2002 |
Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells.
Topics: Adenocarcinoma; Antigens, Differentiation; Antigens, Neoplasm; Breast Neoplasms; Caveolin 1; Caveolin 2; Caveolins; Cell Differentiation; Cell Line; Chromans; Colonic Neoplasms; Dimerization; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, Dominant; Humans; Kidney; Ligands; Macromolecular Substances; Membrane Microdomains; Neoplasm Proteins; Phenotype; Phenylacetates; Prostaglandin D2; Protein Structure, Tertiary; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; RNA, Neoplasm; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Troglitazone; Tumor Cells, Cultured | 2003 |
Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation.
Topics: Anilides; Animals; Asthma; Chemotaxis; Disease Models, Animal; DNA-Binding Proteins; Down-Regulation; Eosinophils; GATA3 Transcription Factor; Humans; Inflammation; Lung; Mice; Mice, Inbred BALB C; Mice, Knockout; Rats; Receptors, Cytoplasmic and Nuclear; Respiratory Hypersensitivity; Rosiglitazone; Thiazoles; Thiazolidinediones; Trans-Activators; Transcription Factors | 2003 |
PPARalpha activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation.
Topics: Binding Sites; Cell Division; Cells, Cultured; Endothelial Cells; Fenofibrate; Gene Expression Regulation; Humans; Luciferases; Neovascularization, Physiologic; Peroxisome Proliferators; Promoter Regions, Genetic; Protein Binding; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; RNA, Messenger; Rosiglitazone; Sp1 Transcription Factor; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
Activation of peroxisome proliferator-activated receptor-gamma in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma.
Topics: Anilides; Animals; Asthma; Cell Movement; Cytokines; Dendritic Cells; Disease Models, Animal; Eosinophils; Inflammation; Lung; Mice; Mice, Inbred BALB C; Ovalbumin; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; T-Lymphocytes; Thiazolidinediones; Transcription Factors; Vasodilator Agents | 2004 |
Effect of peroxisome proliferator activated receptor gamma ligands on growth and gene expression profiles of gastric cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Division; Cyclooxygenase 2; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Isoenzymes; Ligands; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Nuclear Receptor Coactivators; Prostaglandin D2; Prostaglandin-Endoperoxide Synthases; Rosiglitazone; Stomach Neoplasms; Thiazolidinediones; Transcription Factors; Tumor Cells, Cultured | 2004 |
Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones.
Topics: Adipocytes; Adipose Tissue; Cells, Cultured; Chromans; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Plasminogen Activator Inhibitor 1; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transcription, Genetic; Troglitazone | 2004 |
PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas.
Topics: Adenoma; Animals; Annexin A5; Apoptosis; Cell Line; DNA Fragmentation; Female; Gene Expression; Human Growth Hormone; Humans; Ligands; Mice; Mice, Nude; NIH 3T3 Cells; Pituitary Neoplasms; Promoter Regions, Genetic; Rats; Rats, Inbred WF; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transfection | 2004 |
PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis.
Topics: Actins; Anilides; Cell Differentiation; Collagen Type I; Fibroblasts; Humans; Hypoglycemic Agents; Lung; Muscle, Smooth; PPAR gamma; Prostaglandin D2; Pulmonary Fibrosis; Rosiglitazone; Thiazolidinediones; Transforming Growth Factor beta | 2005 |
Selective activation of PPARgamma in breast, colon, and lung cancer cell lines.
Topics: Alitretinoin; Anilides; Breast Neoplasms; Caco-2 Cells; Cell Line, Tumor; Colonic Neoplasms; Female; Gene Expression Regulation, Neoplastic; Genes, Reporter; HT29 Cells; Humans; Ligands; Lung Neoplasms; PPAR gamma; Prostaglandin D2; Retinoid X Receptor alpha; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transfection; Tretinoin | 2005 |
Inhibitors of prostaglandin transport and metabolism augment protease-activated receptor-2-mediated increases in prostaglandin E2 levels and smooth muscle relaxation in mouse isolated trachea.
Topics: Animals; Antiporters; Bromcresol Green; Dinoprostone; DNA-Binding Proteins; Female; Hydroxyprostaglandin Dehydrogenases; Immunohistochemistry; Mice; Mice, Inbred BALB C; Muscle Relaxation; Oligopeptides; Organic Anion Transporters; PPAR gamma; Receptor, PAR-2; Rosiglitazone; Thiazolidinediones; Trachea | 2005 |
Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms.
Topics: Anilides; Cells, Cultured; Endothelium, Vascular; Genes, Reporter; Humans; Hypoglycemic Agents; Ligands; Nitric Oxide; PPAR gamma; Prostaglandin D2; RNA, Small Interfering; Rosiglitazone; Signal Transduction; Thiazolidinediones; Umbilical Veins | 2005 |
The PPARgamma ligand, rosiglitazone, reduces airways hyperresponsiveness in a murine model of allergen-induced inflammation.
Topics: Allergens; Animals; Bronchoalveolar Lavage Fluid; Bronchoconstrictor Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Goblet Cells; Guinea Pigs; Hyperplasia; In Vitro Techniques; Injections, Intraperitoneal; Ligands; Matrix Metalloproteinase 2; Methacholine Chloride; Mice; Mice, Inbred C57BL; Muscle Contraction; Ovalbumin; Pneumonia; PPAR gamma; Respiratory Hypersensitivity; Rosiglitazone; Thiazolidinediones; Time Factors; Trachea; Vasodilator Agents | 2006 |
Thiazolidinediones inhibit albumin uptake by proximal tubular cells through a mechanism independent of peroxisome proliferator activated receptor gamma.
Topics: Albumins; Anilides; Animals; Cells, Cultured; Cholesterol; Chromans; Farnesol; Kidney Tubules, Proximal; Ligands; Mevalonic Acid; Opossums; Polyisoprenyl Phosphates; PPAR gamma; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Troglitazone | 2006 |
Rosiglitazone ameliorates cisplatin-induced renal injury in mice.
Topics: Anilides; Animals; Apoptosis; C-Peptide; Cell Line; Chromans; Cisplatin; Drug Evaluation, Preclinical; Glioma; Humans; Hypoglycemic Agents; Inflammation; Insulin; Intercellular Adhesion Molecule-1; Kidney; Kidney Diseases; Kidney Function Tests; Kidney Tubules, Proximal; Macrophages; Male; Mice; Mice, Inbred C57BL; Monocytes; PPAR gamma; Prostaglandin D2; Protein Transport; Rosiglitazone; Thiazolidinediones; Transcription Factor RelA; Troglitazone; Tumor Necrosis Factor-alpha | 2006 |
Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Carcinoma; Caspase 3; Caspase 7; Caspases; Cell Cycle; Cell Division; Cell Line, Tumor; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Epithelial Cells; Gene Expression; Humans; Insulin-Like Growth Factor I; Intracellular Signaling Peptides and Proteins; Luciferases; Mesoderm; Phosphorylation; PPAR gamma; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Retinoblastoma Protein; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones; Thyroid Neoplasms; Transfection | 2006 |
Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells.
Topics: Animals; Carcinoma, Hepatocellular; Cells, Cultured; Chromans; Cluster Analysis; Gene Expression Profiling; Gene Expression Regulation; Hepatocytes; Humans; Hypoglycemic Agents; Liver Neoplasms; Pioglitazone; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Transcription, Genetic; Troglitazone | 2006 |
Effect of thiazolidinediones on bile acid transport in rat liver.
Topics: Animals; Bile Acids and Salts; Bile Canaliculi; Biological Transport; Cell Membrane; Cholestasis, Intrahepatic; Chromans; Dose-Response Relationship, Drug; Hypoglycemic Agents; Liver; Male; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Transport Vesicles; Troglitazone | 2007 |
Mechanism of thiazolidinedione-dependent cell death in Jurkat T cells.
Topics: Adenosine Triphosphate; Apoptosis; Cell Death; Cell Line, Tumor; Cell Survival; Chromans; Humans; Jurkat Cells; Mitochondria; Necrosis; PPAR gamma; Reactive Oxygen Species; Rosiglitazone; T-Lymphocytes; Thiazolidinediones; Troglitazone | 2007 |
Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor gamma-dependent manner.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Membrane; Colorectal Neoplasms; Dose-Response Relationship, Drug; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Pioglitazone; PPAR gamma; Receptors, CXCR4; Rosiglitazone; Thiazolidinediones | 2007 |
Mechanism of TNFalpha-induced IL-1alpha, IL-1beta and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones.
Topics: Analysis of Variance; Antibodies, Monoclonal; Cells, Cultured; Chromans; Coronary Disease; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukin-1alpha; Interleukin-1beta; Interleukin-6; Interleukins; Myocytes, Cardiac; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Signal Transduction; Simvastatin; Stimulation, Chemical; Thiazolidinediones; Troglitazone; Tumor Necrosis Factor-alpha | 2007 |
Investigation of the lipophilic behaviour of some thiazolidinediones. Relationships with PPAR-gamma activity.
Topics: Chromans; Chromatography, High Pressure Liquid; Hydrogen-Ion Concentration; Lipids; Membranes, Artificial; Octanols; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transcriptional Activation; Troglitazone; Water | 2007 |
PPARgamma inhibits osteogenesis via the down-regulation of the expression of COX-2 and iNOS in rats.
Topics: Aging; Animals; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Cell Differentiation; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2; Down-Regulation; Gene Expression Regulation, Enzymologic; Ligands; Nitric Oxide; Nitric Oxide Synthase Type II; Osteoblasts; Osteogenesis; PPAR gamma; Prostaglandin D2; Rats; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors; Transforming Growth Factor beta | 2007 |
Anti-inflammatory lipid mediator 15d-PGJ2 inhibits translation through inactivation of eIF4A.
Topics: Anti-Inflammatory Agents; Arachidonic Acid; Arsenites; Chromans; Cyclopentanes; Cytoplasmic Granules; Dinoprostone; Emetine; Enzyme Inhibitors; Eukaryotic Initiation Factor-2; Eukaryotic Initiation Factor-4A; Gene Expression Regulation; HeLa Cells; Humans; Hypoglycemic Agents; Inflammation; Poly(A)-Binding Proteins; PPAR gamma; Prostaglandin D2; Prostaglandins A; Protein Biosynthesis; Protein Synthesis Inhibitors; Rosiglitazone; Signal Transduction; Sodium Compounds; T-Cell Intracellular Antigen-1; Thiazolidinediones; TNF Receptor-Associated Factor 2; Troglitazone; Tumor Necrosis Factor-alpha | 2007 |
Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARgamma-dependent and PPARgamma-independent pathways.
Topics: Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Humans; Male; PPAR gamma; Prostatic Neoplasms; RNA, Small Interfering; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2009 |
Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.
Topics: Animals; Animals, Newborn; Astrocytes; Biomarkers; Brain; Butyrates; Cells, Cultured; Cyclooxygenase 2; Drug Combinations; Gene Expression Regulation, Enzymologic; Glial Fibrillary Acidic Protein; Lipopolysaccharides; Peroxisome Proliferator-Activated Receptors; Phenoxyacetates; Phenylurea Compounds; PPAR alpha; PPAR delta; PPAR gamma; PPAR-beta; Protein Isoforms; Rats; Rosiglitazone; Thiazolidinediones; Time Factors | 2009 |
Rosiglitazone prevents high glucose-induced vascular endothelial growth factor and collagen IV expression in cultured mesangial cells.
Topics: AMP-Activated Protein Kinases; Animals; Cells, Cultured; Chromans; Collagen Type IV; Dose-Response Relationship, Drug; Gene Expression Regulation; Glucose; Membranes; Mesangial Cells; NADPH Oxidases; Oxidative Stress; PPAR gamma; Protein Kinase C; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Response Elements; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transfection; Troglitazone; Vascular Endothelial Growth Factor A | 2009 |
Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels.
Topics: Apoptosis; Calcium; Calcium Channels; Caspase 3; Caspase 9; Cell Division; Cells, Cultured; Chromans; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Membrane Potential, Mitochondrial; Oxazines; p38 Mitogen-Activated Protein Kinases; Peroxisome Proliferator-Activated Receptors; Phenoxyacetates; Phenylpropionates; Rosiglitazone; Thiazolidinediones; Troglitazone; Urothelium | 2009 |
Hepatitis C virus NS5A protein increases hepatic lipid accumulation via induction of activation and expression of PPARgamma.
Topics: Animals; Cell Line; Gene Expression Regulation; Heat-Shock Proteins; Humans; Hypoglycemic Agents; Lipid Metabolism; Liver; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; PPAR gamma; RNA Interference; Rosiglitazone; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Viral Nonstructural Proteins | 2009 |
The PPARγ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells.
Topics: Androgen-Binding Protein; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Dihydrotestosterone; Gene Expression; Genes, Reporter; Humans; Hypoglycemic Agents; Male; Mutation; Neoplasms, Hormone-Dependent; PPAR gamma; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones; Transfection | 2010 |
Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner.
Topics: Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromans; Female; Gene Expression; Humans; Ovarian Neoplasms; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Troglitazone | 2011 |
Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery.
Topics: Animals; Cell Line; Cell Membrane; Chromans; Drug Discovery; Gramicidin; Insulin; Ion Channels; Lipid Bilayers; Membrane Potentials; Membrane Proteins; Pioglitazone; PPAR gamma; Rats; Rosiglitazone; Sodium Channels; Thiazolidinediones; Troglitazone | 2011 |
Increasing doxorubicin activity against breast cancer cells using PPARγ-ligands and by exploiting circadian rhythms.
Topics: Animals; Animals, Newborn; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Cycle; Cells, Cultured; Collagen; Doxorubicin; Drug Chronotherapy; Female; Fibroblasts; Humans; Ligands; MCF-7 Cells; Melatonin; Myocytes, Cardiac; PPAR gamma; Rats; Rosiglitazone; Sarcomeres; Thiazolidinediones | 2013 |
Various peroxisome proliferator-activated receptor (PPAR)-γ agonists differently induce differentiation of cultured human keratinocytes.
Topics: Anti-Inflammatory Agents; Benzimidazoles; Benzoates; Cell Differentiation; Cells, Cultured; Chromans; Filaggrin Proteins; Gene Expression Regulation; Humans; Intermediate Filament Proteins; Keratinocytes; Membrane Proteins; Microscopy, Fluorescence; Pioglitazone; PPAR gamma; RNA, Messenger; Rosiglitazone; Skin; Telmisartan; Thiazolidinediones; Troglitazone | 2015 |
Thiazolidinediones abrogate cervical cancer growth.
Topics: Animals; Cell Differentiation; Cell Proliferation; Complement Factor D; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Mice; Papillomaviridae; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Uterine Cervical Neoplasms | 2017 |